{"id":135806,"date":"2026-10-28T19:02:45","date_gmt":"2026-10-28T10:02:45","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/4523-20261028-01_wp_financial_summary\/"},"modified":"2026-10-28T19:02:45","modified_gmt":"2026-10-28T10:02:45","slug":"4523-20261028-01_wp_financial_summary","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-4523\/ir\/4523-20261028-01_wp_financial_summary\/","title":{"rendered":"Flash Report on Revenue from Anti-Amyloid beta Antibody Leqembi\u00ae"},"content":{"rendered":"<p>Interim period revenue was 61.5 hundred million yen (615 hundred million yen). United States 32.5 hundred million yen (325 hundred million yen), Japan 13.0 hundred million yen (130 hundred million yen), China 9.7 hundred million yen (97 hundred million yen). Prior-year same period was 41.1 hundred million yen (411 hundred million yen). Earnings announcement scheduled for November 10, 2026. Co-commercialization and joint promotion of lecanemab are led by Eisai.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4523","jir_company_name":"Eisai Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-28","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4523-20261028-01.pdf","jir_short_summary":"Interim period revenue was 61.5 hundred million yen (615 hundred million yen). United States 32.5 hundred million yen (325 hundred million yen), Japan 13.0 hundred million yen (130 hundred million yen), China 9.7 hundred million yen (97 hundred million yen). Prior-year same period was 41.1 hundred million yen (411 hundred million yen). Earnings announcement scheduled for November 10, 2026. Co-commercialization and joint promotion of lecanemab are led by Eisai.","jir_summary":"### Performance Overview\nEisai Co., Ltd. has published a flash report on global revenue for the anti-amyloid beta antibody Leqembi\u00ae. Interim period (2026-04-01 to 2026-09-30) revenue totaled 615 hundred million yen, with country breakdowns of United States 325 hundred million yen, Japan 130 hundred million yen, and China 97 hundred million yen. The prior-year same period was 411 hundred million yen, and revenues in the United States, Japan, and China in particular exceeded the prior-year levels. The earnings announcement is scheduled for November 10, 2026, and further details are expected to be disclosed at that time.\n\n### Outlook and Collaboration\nFor lecanemab, Eisai Co., Ltd. is leading global development and regulatory submissions, and Eisai and Biogen will conduct co-commercialization and joint promotion. Interim sales trends will be reflected in full-year 2026 performance disclosures, and detailed performance indicators and guidance are expected to be provided in the upcoming earnings announcement.","jir_financial_highlights":"Revenue (Global, unaudited figures): 615 hundred million yen (Year-over-Year Unknown (prior-year same period: 411 hundred million yen))\nU.S. revenue: 325 hundred million yen (Year-over-Year increase)\nJapan revenue: 130 hundred million yen (Year-over-Year increase)\nChina revenue: 97 hundred million yen (Year-over-Year increase)","jir_category":"","jir_hashtags":"#Eisai, #Leqembi, #AntiAmyloidBeta, #InterimPeriodRevenue","jir_key_figures":"615 hundred million yen: Interim period revenue\nUnited States 325 hundred million yen\nJapan 130 hundred million yen\nChina 97 hundred million yen\nPrior-year same period 411 hundred million yen","jir_meta_title":"Eisai Co., Ltd. \u2014 Leqembi Revenue Flash: 615 hundred million yen, Country Breakdown Released","jir_meta_description":"Interim revenue for Eisai Co., Ltd.'s anti-amyloid beta antibody Leqembi\u00ae was 615 hundred million yen. United States 325 hundred million yen, Japan 130 hundred million yen, China 97 hundred million yen. Earnings announcement scheduled for November 10, 2026. Summary includes co-promotion framework.","jir_og_title":"Eisai Co., Ltd. Leqembi Revenue Flash: Interim Results of 615 hundred million yen","jir_og_description":"Leqembi interim sales totaled 615 hundred million yen. Country breakdown: US 325, Japan 130, China 97 hundred million yen. Earnings announcement scheduled for November 10. Co-promotion arrangements noted.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7482,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-135806","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Flash Report on Revenue from Anti-Amyloid beta Antibody Leqembi\u00ae - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4523\/ir\/4523-20261028-01_wp_financial_summary\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4523\/ir\/4523-20261028-01_wp_financial_summary\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4523\/ir\/4523-20261028-01_wp_financial_summary\/\",\"name\":\"Flash Report on Revenue from Anti-Amyloid beta Antibody Leqembi\u00ae - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-10-28T10:02:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4523\/ir\/4523-20261028-01_wp_financial_summary\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4523\/ir\/4523-20261028-01_wp_financial_summary\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4523\/ir\/4523-20261028-01_wp_financial_summary\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Flash Report on Revenue from Anti-Amyloid beta Antibody Leqembi\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Flash Report on Revenue from Anti-Amyloid beta Antibody Leqembi\u00ae - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4523\/ir\/4523-20261028-01_wp_financial_summary\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4523\/ir\/4523-20261028-01_wp_financial_summary\/","url":"https:\/\/japanir.jp\/en\/company\/company-4523\/ir\/4523-20261028-01_wp_financial_summary\/","name":"Flash Report on Revenue from Anti-Amyloid beta Antibody Leqembi\u00ae - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-10-28T10:02:45+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4523\/ir\/4523-20261028-01_wp_financial_summary\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4523\/ir\/4523-20261028-01_wp_financial_summary\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4523\/ir\/4523-20261028-01_wp_financial_summary\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Flash Report on Revenue from Anti-Amyloid beta Antibody Leqembi\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"7482","title":"EISAI CO LTD","ticker":"4523"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/135806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=135806"}],"version-history":[{"count":0,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/135806\/revisions"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=135806"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=135806"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=135806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}